FOLH1 and prostate cancer: Baranski et al. [12] (Heidelberg, Germany) presented a study on a novel dual labelled compound based on PSMA-11 (Fig. 5) evaluating the potential of a combination of preoperative staging by PET/CT and fluorescence-guided surgery for detecting metastasis or neoplastic lymph nodes in patients with prostate cancer.